A systematic review of the A118G (Asn40Asp) variant of OPRM1 in relation to smoking initiation, nicotine dependence and smoking cessation

Pharmacogenomics

Volumn 13, Issue 8, 2012, Pages 917-933

  Verhagen, Maaike ^a   Kleinjan, Marloes ^a   Engels, Rutger Cme ^a  

^a RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

Author keywords

opioid system; A118G; Asn40Asp; OPRM1; smoking behaviors

Indexed keywords

ADENINE; ASPARAGINE; ASPARTIC ACID; BETA ENDORPHIN; GUANINE; MU OPIATE RECEPTOR; NICOTINE; NICOTINE PATCH; PLACEBO;

ALLELE; CIGARETTE SMOKING; DESCRIPTIVE RESEARCH; DISEASE COURSE; DOPAMINERGIC GENE; DRUG DOSE REDUCTION; GENE; GENE FUNCTION; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HAPLOTYPE; HERITABILITY; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MOLECULAR GENETICS; MU OPIOID RECEPTOR GENE; NICOTINE REPLACEMENT THERAPY; PHENOTYPE; RECEPTOR BINDING; REVIEW; SEROTONINERGIC GENE; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING CESSATION; SMOKING HABIT; SYSTEMATIC REVIEW; TOBACCO DEPENDENCE; TREATMENT RESPONSE;

ALLELES; GENETIC VARIATION; GENOTYPE; HUMANS; POLYMORPHISM, GENETIC; RECEPTORS, OPIOID, MU; SMOKING; SMOKING CESSATION; TOBACCO USE DISORDER;

EID: 84862008447     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.76     Document Type: Review

References (145)

1. Mayhew KP, Flay BR, Mott JA. Stages in the development of adolescent smoking. Drug Alcohol. Depend. 59(Suppl. 1), S61-S81 (2000).
2. Benowitz NL, Henningfield JE. Establishing a nicotine threshold for addiction. The implications for tobacco regulation. N. Engl. J. Med. 331(2), 123-125 (1994).
3. Benowitz NL. Nicotine addiction. N. Engl. J. Med. 362(24), 2295-2303 (2010).
4. DiFranza JR, Wellman RJ. A sensitization-homeostasis model of nicotine craving, withdrawal, and tolerance: integrating the clinical and basic science literature. Nicotine Tob. Res. 7(1), 9-26 (2005).
5. Audrain-McGovern J, Al Koudsi N, Rodriguez D, Wileyto EP, Shields PG, Tyndale RF. The role of CYP2A6 in the emergence of nicotine dependence in adolescents. Pediatrics 119(1), e264-e274 (2007).
6. Breslau N, Kilbey MM, Andreski P. DSM-III-R nicotine dependence in young adults: prevalence, correlates and associated psychiatric disorders. Addiction 89(6), 743-754 (1994).
7. Stolerman IP, Jarvis MJ. The scientific case that nicotine is addictive. Psychopharmacology (Berl.). 117(1), 2-10; discussion 14-20 (1995).
8. Pidoplichko VI, DeBiasi M, Williams JT, Dani JA. Nicotine activates and desensitizes midbrain dopamine neurons. Nature 390(6658), 401-404 (1997).
9. Pontieri FE, Tanda G, Orzi F, Di Chiara G. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature 382(6588), 255-257 (1996).
10. Salokangas RK, Vilkman H, Ilonen T et al. High levels of dopamine activity in the basal ganglia of cigarette smokers. Am. J. Psychiatry 157(4), 632-634 (2000).
11. Koob GF. Neurobiology of addiction. Toward the development of new therapies. Ann. NY Acad. Sci. 909, 170-185 (2000).
12. Laviolette SR, van der Kooy D. Blockade of mesolimbic dopamine transmission dramatically increases sensitivity to the rewarding effects of nicotine in the ventral tegmental area. Mol. Psychiatry 8(1), 50-59, 59 (2003).
13. Stein EA, Pankiewicz J, Harsch HH et al. Nicotine-induced limbic cortical activation in the human brain: a functional MRI study. Am. J. Psychiatry 155(8), 1009-1015 (1998).
14. Davenport KE, Houdi AA, Van Loon GR. Nicotine protects against mu-opioid receptor antagonism by beta-funaltrexamine: evidence for nicotine-induced release of endogenous opioids in brain. Neurosci. Lett. 113(1), 40-46 (1990).
15. Pomerleau OF. Endogenous opioids and smoking: a review of progress and problems. Psychoneuroendocrinology 23(2), 115-130 (1998).
16. Ray R, Jepson C, Patterson F et al. Association of OPRM1 A118G variant with the relative reinforcing value of nicotine. Psychopharmacology (Berl.) 188(3), 355-363 (2006).
17. Walters CL, Cleck JN, Kuo YC, Blendy JA. Mu-opioid receptor and CREB activation are required for nicotine reward. Neuron 46(6), 933-943 (2005).
18. DiFranza JR, Rigotti NA, McNeill AD et al. Initial symptoms of nicotine dependence in adolescents. Tob. Control. 9(3), 313-319 (2000).
19. Li MD, Cheng R, Ma JZ, Swan GE. A meta-analysis of estimated genetic and environmental effects on smoking behavior in male and female adult twins. Addiction 98(1), 23-31 (2003).
20. Maes HH, Sullivan PF, Bulik CM et al. A twin study of genetic and environmental influences on tobacco initiation, regular tobacco use and nicotine dependence. Psychol. Med. 34(7), 1251-1261 (2004).
21. Vink JM, Willemsen G, Boomsma DI. Heritability of smoking initiation and nicotine dependence. Behav. Genet. 35(4), 397-406 (2005).
22. Heath AC, Kirk KM, Meyer JM, Martin NG. Genetic and social determinants of initiation and age at onset of smoking in Australian twins. Behav. Genet. 29(6), 395-407 (1999).
23. Sullivan PF, Kendler KS. The genetic epidemiology of smoking. Nicotine Tob. Res. 1(Suppl. 2), S51-S57 (1999).
24. Rose RJ, Broms U, Korhonen T, Dick DM, Kaprio J. Genetics of smoking behavior. In: Handbook of Behavior Genetics. Kim YK (Ed.). Springer, NY, USA, 411-431 (2009).
25. Haberstick BC, Timberlake D, Ehringer MA et al. Genes, time to first cigarette and nicotine dependence in a general population sample of young adults. Addiction 102(4), 655-665 (2007).
26. Kendler KS, Neale MC, Sullivan P, Corey LA, Gardner CO, Prescott CA. A population-based twin study in women of smoking initiation and nicotine dependence. Psychol. Med. 29(2), 299-308 (1999).
27. Maes HH, Neale MC, Kendler KS, Martin NG, Heath AC, Eaves LJ. Genetic and cultural transmission of smoking initiation: an extended twin kinship model. Behav. Genet. 36(6), 795-808 (2006).
28. True WR, Xian H, Scherrer JF et al. Common genetic vulnerability for nicotine and alcohol dependence in men. Arch. Gen. Psychiatry 56(7), 655-661 (1999).
29. Han C, McGue MK, Iacono WG. Lifetime tobacco, alcohol and other substance use in adolescent Minnesota twins: univariate and multivariate behavioral genetic analyses. Addiction 94(7), 981-993 (1999).
30. Broms U, Silventoinen K, Madden PA, Heath AC, Kaprio J. Genetic architecture of smoking behavior: a study of Finnish adult twins. Twin Res. Hum. Genet. 9(1), 64-72 (2006).
31. Hardie TL, Moss HB, Lynch KG. Genetic correlations between smoking initiation and smoking behaviors in a twin sample. Addict. Behav. 31(11), 2030-2037 (2006).
32. Xian H, Scherrer JF, Madden PA et al. The heritability of failed smoking cessation and nicotine withdrawal in twins who smoked and attempted to quit. Nicotine Tob. Res. 5(2), 245-254 (2003).
33. Munafo MR, Johnstone EC. Genes and cigarette smoking. Addiction 103(6), 893-904 (2008).
34. Munafo M, Clark T, Johnstone E, Murphy M, Walton R. The genetic basis for smoking behavior: a systematic review and meta-analysis. Nicotine Tob. Res. 6(4), 583-597 (2004). General overview of genes associated with smoking behaviors.
35. Schnoll RA, Johnson TA, Lerman C. Genetics and smoking behavior. Curr. Psychiatry Rep. 9(5), 349-357 (2007).
36. Vink JM, Smit AB, de Geus EJ et al. Genome-wide association study of smoking initiation and current smoking. Am. J. Hum. Genet. 84(3), 367-379 (2009). First genome-wide association study describing an OPRM1 gene effect on smoking initiation.
37. Bierut LJ, Madden PA, Breslau N et al. Novel genes identified in a high-density genome wide association study for nicotine dependence. Hum. Mol. Genet. 16(1), 24-35 (2007).
38. Lind PA, Macgregor S, Vink JM et al. A genomewide association study of nicotine and alcohol dependence in Australian and Dutch populations. Twin Res. Hum. Genet. 13(1), 10-29 (2010).
39. Uhl GR, Drgon T, Johnson C, Ramoni MF, Behm FM, Rose JE. Genome-wide association for smoking cessation success in a trial of precessation nicotine replacement. Mol. Med. 16(11-12), 513-526 (2010).
40. Uhl GR, Drgon T, Johnson C et al. Genomewide association for smoking cessation success: participants in the Patch in Practice trial of nicotine replacement. Pharmacogenomics 11(3), 357-367 (2010).
41. Caporaso N, Gu F, Chatterjee N et al. Genomewide and candidate gene association study of cigarette smoking behaviors. PLoS ONE 4(2), e4653 (2009).
42. Berrettini W, Yuan X, Tozzi F et al. Alpha-5/alpha-3 nicotinic receptor subunit alleles increase risk for heavy smoking. Mol. Psychiatry 13(4), 368-373 (2008).
43. Thorgeirsson TE, Gudbjartsson DF, Surakka I et al. Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior. Nat. Genet. 42(5), 448-453 (2010).
44. Arias A, Feinn R, Kranzler HR. Association of an Asn40Asp (A118G) polymorphism in the mu-opioid receptor gene with substance dependence: a meta-analysis. Drug Alc. Depend. 83(3), 262-268 (2006). Extensive meta-analysis on the association between OPRM1 A118G and substance dependence.
45. Balfour DJ. The neurobiology of tobacco dependence: a preclinical perspective on the role of the dopamine projections to the nucleus accumbens [corrected]. Nicotine Tob. Res. 6(6), 899-912 (2004).
46. Berrendero F, Kieffer BL, Maldonado R. Attenuation of nicotine-induced antinociception, rewarding effects, and dependence in mu-opioid receptor knock-out mice. J. Neurosci. 22(24), 10935-10940 (2002). Animal study providing a clear description of involvement of the μ-opioid receptors in nicotine-related behaviors.
47. Bond C, LaForge KS, Tian M et al. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc. Natl Acad. Sci. USA 95(16), 9608-9613 (1998).
48. Ball D, Collier D. Substance misuse. In: Psychiatric Genetics & Genomics. McGuffin P, Owen MJ, Gottesman II (Eds). Oxford University Press, Oxford, UK, 267-302 (2002).
49. Lerman C, Wileyto EP, Patterson F et al. The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. Pharmacogenomics J. 4(3), 184-192 (2004).
50. Beyer A, Koch T, Schroder H, Schulz S, Hollt V. Effect of the A118G polymorphism on binding affinity, potency and agonistmediated endocytosis, desensitization, and resensitization of the human mu-opioid receptor. J. Neurochem. 89(3), 553-560 (2004).
51. Zhang Y, Wang D, Johnson AD, Papp AC, Sadee W. Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J. Biol. Chem. 280(38), 32618-32624 (2005).
52. Mague SD, Blendy JA. OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models. Drug Alcohol. Depend. 108(3), 172-182 (2010). Clear review describing the functional relevance of the A118G SNP.
53. Mague SD, Isiegas C, Huang P, Liu-Chen LY, Lerman C, Blendy JA. Mouse model of OPRM1 (A118G) polymorphism has sex-specific effects on drug-mediated behavior. Proc. Natl Acad. Sci. USA 106(26), 10847-10852 (2009).
54. Vink JM, Willemsen G, Beem AL, Boomsma DI. The Fagerstrom Test for Nicotine Dependence in a Dutch sample of daily smokers and ex-smokers. Addict. Behav. 30(3), 575-579 (2005).
55. Bergen AW, Conti DV, Van Den Berg D et al. Dopamine genes and nicotine dependence in treatment-seeking and community smokers. Neuropsychopharmacology 34(10), 2252-2264 (2009).
56. Conti DV, Lee W, Li D et al. Nicotinic acetylcholine receptor beta2 subunit gene implicated in a systems-based candidate gene study of smoking cessation. Hum. Mol. Genet. 17(18), 2834-2848 (2008).
57. Becker KG, Barnes KC, Bright TJ, Wang SA. The genetic association database. Nat. Genet. 36(5), 431-432 (2004).
58. Hindorff LA, Sethupathy P, Junkins HA et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc. Natl Acad. Sci. USA 106(23), 9362-9367 (2009).
59. LaForge KS, Yuferov V, Kreek MJ. Opioid receptor and peptide gene polymorphisms: potential implications for addictions. Eur. J. Pharmacol. 410(2-3), 249-268 (2000).
60. Crowley JJ, Oslin DW, Patkar AA et al. A genetic association study of the mu opioid receptor and severe opioid dependence. Psychiatr. Genet. 13(3), 169-173 (2003).
61. Gelernter J, Kranzler H, Cubells J. Genetics of two mu opioid receptor gene (OPRM1) exon I polymorphisms: population studies, and allele frequencies in alcohol- and drug-dependent subjects. Mol. Psychiatry 4(5), 476-483 (1999).
62. Li T, Liu X, Zhu ZH et al. Association analysis of polymorphisms in the mu opioid gene and heroin abuse in Chinese subjects. Addict. Biol. 5(2), 181-186 (2000).
63. Hardin J, He Y, Javitz HS et al. Nicotine withdrawal sensitivity, linkage to chr6q26, and association of OPRM1 SNPs in the SMOking in FAMilies (SMOFAM) sample. Cancer Epidemiol. Biomarkers. Prev. 18(12), 3399-3406 (2009).
64. Perkins KA, Lerman C, Coddington S et al. Gene and gene by sex associations with initial sensitivity to nicotine in nonsmokers. Behav. Pharmacol. 19(5-6), 630-640 (2008).
65. Perkins KA, Lerman C, Grottenthaler A et al. Dopamine and opioid gene variants are associated with increased smoking reward and reinforcement owing to negative mood. Behav. Pharmacol. 19(5-6), 641-649 (2008).
66. Ray R, Jepson C, Wileyto EP et al. Genetic variation in mu-opioid-receptor-interacting proteins and smoking cessation in a nicotine replacement therapy trial. Nicotine Tob. Res. 9(11), 1237-1241 (2007).
67. Munafo MR, Elliot KM, Murphy MF, Walton RT, Johnstone EC. Association of the mu-opioid receptor gene with smoking cessation. Pharmacogenomics J. 7(5), 353-361 (2007).
68. Wang Z, Ray R, Faith M et al. Nicotine abstinence-induced cerebral blood flow changes by genotype. Neurosci. Lett. 438(3), 275-280 (2008).
69. Zhang L, Kendler KS, Chen X. The mu-opioid receptor gene and smoking initiation and nicotine dependence. Behav. Brain Funct. 2, 28 (2006).
70. Drgon T, Johnson C, Walther D, Albino AP, Rose JE, Uhl GR. Genome-wide association for smoking cessation success: participants in a trial with adjunctive denicotinized cigarettes. Mol. Med. 15(7-8), 268-274 (2009).
71. Drgon T, Montoya I, Johnson C et al. Genome-wide association for nicotine dependence and smoking cessation success in NIH research volunteers. Mol. Med. 15(1-2), 21-27 (2009).
72. Liu YZ, Pei YF, Guo YF et al. Genome-wide association analyses suggested a novel mechanism for smoking behavior regulated by IL15. Mol. Psychiatry 14(7), 668-680 (2009).
73. Thorgeirsson TE, Geller F, Sulem P et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 452(7187), 638-642 (2008).
74. Uhl GR, Liu QR, Drgon T, Johnson C, Walther D, Rose JE. Molecular genetics of nicotine dependence and abstinence: whole genome association using 520,000 SNPs. BMC Genet. 8, 10 (2007).
75. Uhl GR, Liu QR, Drgon T et al. Molecular genetics of successful smoking cessation: convergent genome-wide association study results. Arch. Gen. Psychiatry 65(6), 683-693 (2008).
76. Fagerström KO. Measuring degree of physical dependence to tobacco smoking with reference to individualization of treatment. Addict. Behav. 3(3-4), 235-241 (1978).
77. Gilbert D, McClernon J, Rabinovich N et al. Effects of quitting smoking on EEG activation and attention last for more than 31 days and are more severe with stress, dependence, DRD2 A1 allele, and depressive traits. Nicotine Tob. Res. 6(2), 249-267 (2004).
78. Javitz HS, Brigham J, Lessov-Schlaggar CN, Krasnow RE, Swan GE. Association of tobacco dependence and quit attempt duration with Rasch-modeled withdrawal sensitivity using retrospective measures. Addiction 104(6), 1027-1035 (2009).
79. ICRF. Effectiveness of a nicotine patch in helping people stop smoking: results of a randomised trial in general practice. Imperial Cancer Research Fund General Practice Research Group. BMJ 306(6888), 1304-1308 (1993).
80. Befort K, Filliol D, Decaillot FM, Gaveriaux-Ruff C, Hoehe MR, Kieffer BL. A single nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs receptor signaling. J. Biol. Chem. 276(5), 3130-3137 (2001).
81. Dickersin K. The existence of publication bias and risk factors for its occurrence. JAMA 263(10), 1385-1389 (1990).
82. Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG. Replication validity of genetic association studies. Nat. Genet. 29(3), 306-309 (2001).
83. Munafo MR, Johnstone EC, Guo B, Murphy MF, Aveyard P. Association of COMT Val108/158Met genotype with smoking cessation. Pharmacogenet. Genomics 18(2), 121-128 (2008).
84. Omidvar M, Stolk L, Uitterlinden AG, Hofman A, Van Duijn CM, Tiemeier H. The effect of catechol-O-methyltransferase Met/Val functional polymorphism on smoking cessation: retrospective and prospective analyses in a cohort study. Pharmacogenet. Genomics 19(1), 45-51 (2009).
85. Ray R, Ruparel K, Newberg A et al. Human mu opioid receptor (OPRM1 A118G) polymorphism is associated with brain mu-opioid receptor binding potential in smokers. Proc. Natl Acad. Sci. USA 108(22), 9268-9273 (2011).
86. Ramchandani VA, Umhau J, Pavon FJ et al. A genetic determinant of the striatal dopamine response to alcohol in men. Mol. Psychiatry 16(8), 809-817 (2012).
87. Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am. J. Psychiatry 160(4), 636-645 (2003).
88. De Geus E, Goldberg T, Boomsma DI, Posthuma D. Imaging the genetics of brain structure and function. Biol. Psychol. 79(1), 1-8 (2008). Interesting paper on genetic imaging perspectives.
89. De Leeuw RN, Engels RC, Scholte RH. Parental smoking and pretend smoking in young children. Tob. Control. 19(3), 201-205 (2010).
90. De Leeuw RN, Verhagen M, de Wit C, Scholte RH, Engels RC. 'One cigarette for you and one for me': children of smoking and non-smoking parents during pretend play. Tob. Control. 20(5), 344-348 (2011).
91. Rutter M, Dunn J, Plomin R et al. Integrating nature and nurture: implications of person-environment correlations and interactions for developmental psychopathology. Dev. Psychopathol. 9(2), 335-364 (1997).
92. Dick DM, Viken R, Purcell S, Kaprio J, Pulkkinen L, Rose RJ. Parental monitoring moderates the importance of genetic and environmental influences on adolescent smoking. J. Abnorm. Psychol. 116(1), 213-218 (2007).
93. Avenevoli S, Merikangas KR. Familial influences on adolescent smoking. Addiction 98(Suppl. 1), 1-20 (2003).
94. Henriksen L, Jackson C. Anti-smoking socialization: relationship to parent and child smoking status. Health Commun. 10(1), 87-101 (1998).
95. Jackson C, Henriksen L. Do as I say: parent smoking, antismoking socialization, and smoking onset among children. Addict. Behav. 22(1), 107-114 (1997).
96. Xie P, Kranzler HR, Zhang H et al. Childhood adversity increases risk for nicotine dependence and interacts with alpha5 nicotinic acetylcholine receptor genotype specifically in males. Neuropsychopharmacology 37(3), 669-676 (2012).
97. Benowitz NL, Lessov-Schlaggar CN, Swan GE, Jacob P 3rd. Female sex and oral contraceptive use accelerate nicotine metabolism. Clin. Pharmacol. Ther. 79(5), 480-488 (2006).
98. Verhagen M, van der Meij A, van Deurzen PA et al. Meta-analysis of the BDNF Val66Met polymorphism in major depressive disorder: effects of gender and ethnicity. Mol. Psychiatry 15(3), 260-271 (2010).
99. Perkins KA, Scott J. Sex differences in long-term smoking cessation rates due to nicotine patch. Nicotine Tob. Res. 10(7), 1245-1250 (2008).
100. Zubieta JK, Dannals RF, Frost JJ. Gender and age influences on human brain mu-opioid receptor binding measured by PET. Am. J. Psychiatry 156(6), 842-848 (1999).
101. Micevych PE, Rissman EF, Gustafsson JA, Sinchak K. Estrogen receptor-alpha is required for estrogen-induced mu-opioid receptor internalization. J. Neurosci. Res. 71(6), 802-810 (2003).
102. Mills RH, Sohn RK, Micevych PE. Estrogen-induced mu-opioid receptor internalization in the medial preoptic nucleus is mediated via neuropeptide Y-Y1 receptor activation in the arcuate nucleus of female rats. J. Neurosci. 24(4), 947-955 (2004).
103. Cicero TJ, Aylward SC, Meyer ER. Gender differences in the intravenous selfadministration of mu opiate agonists. Pharmacol. Biochem. Behav. 74(3), 541-549 (2003).
104. Craft RM, Kalivas PW, Stratmann JA. Sex differences in discriminative stimulus effects of morphine in the rat. Behav. Pharmacol. 7(8), 764-778 (1996).
105. Funck-Brentano C, Boelle PY, Verstuyft C, Bornert C, Becquemont L, Poirier JM. Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects. Eur. J. Clin. Pharmacol. 61, 821-829 (2005).
106. Johnson RE, Eissenberg T, Stitzer ML, Strain EC, Liebson IA, Bigelow GE. A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. Drug Alcohol Depend. 40, 17-25 (1995).
107. King BF, Dacquet C, Ziganshin AU et al. Potentiation by 2,2′-pyridylisatogen tosylate of ATP-responses at a recombinant P2Y1 purinoceptor. Br. J. Pharmacol. 117, 1111-1118 (1996).
108. Quednow BB, Csomor PA, Chmiel J, Beck T, Vollenweider FX. Sensorimotor gating and attentional set-shifting are improved by the mu-opioid receptor agonist morphine in healthy human volunteers. Int. J. Neuropsychopharmacol. 11, 655-669 (2008).
109. Strong JA, Dalvi A, Revilla FJ et al. Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson's disease. Mov. Disord. 21, 654-659 (2006).
110. Contet C, Kieffer BL, Befort K. Mu opioid receptor: a gateway to drug addiction. Curr. Opin. Neurobiol. 14, 370-378 (2004).
111. Mutschler NH, Stephen BJ, Teoh SK, Mendelson JH, Mello NK. An inpatient study of the effects of buprenorphine on cigarette smoking in men concurrently dependent on cocaine and opioids. Nicotine Tob. Res. 4, 223-228 (2002).
112. Ross S, Peselow E. Pharmacotherapy of addictive disorders. Clin. Neuropharmacol. 32, 277-289 (2009).
113. Saccone SF, Hinrichs AL, Saccone NL et al. Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. Hum. Mol. Genet. 16, 36-49 (2007).
114. Scott DJ, Domino EF, Heitzeg MM et al. Smoking modulation of mu-opioid and dopamine D2 receptor-mediated neurotransmission in humans. Neuropsychopharmacology 32, 450-457 (2007).
115. Sullivan PF, Neale BM, Van Den Oord E et al. Candidate genes for nicotine dependence via linkage, epistasis, and bioinformatics. Am. J. Med. Genet. 126B, 23-36 (2004).
116. Balerio GN, Aso E, Maldonado R. Involvement of the opioid system in the effects induced by nicotine on anxiety-like behaviour in mice. Psychopharmacology 181, 260-269 (2005).
117. Berrendero F, Kieffer BL, Maldonado R. Attenuation of nicotine-induced antinociception, rewarding effects, and dependence in mu-opioid receptor knock-out mice. J. Neurosci. 22, 10935-10940 (2002).
118. Corrigall WA, Coen KM, Adamson KL, Chow BL. Manipulations of mu-opioid and nicotinic cholinergic receptors in the pontine tegmental region alter cocaine self-administration in rats. Psychopharmacology 145, 412-417 (1999).
119. Corrigall WA, Coen KM, Adamson KL, Chow BL, Zhang J. Response of nicotine self-administration in the rat to manipulations of mu-opioid and gamma-aminobutyric acid receptors in the ventral tegmental area. Psychopharmacology 149, 107-114 (2000).
120. Davenport KE, Houdi AA, Van Loon GR. Nicotine protects against mu-opioid receptor antagonism by beta-funaltrexamine: evidence for nicotine-induced release of endogenous opioids in brain. Neurosci. Lett. 113, 40-46 (1990).
121. Evans RG, Ludbrook J. Chemosensitive cardiopulmonary afferents and the haemodynamic response to simulated haemorrhage in conscious rabbits. Br. J. Pharmacol. 102, 533-539 (1991).
122. Galeote L, Kieffer BL, Maldonado R, Berrendero F. Mu-opioid receptors are involved in the tolerance to nicotine antinociception. J. Neurochem. 97, 416-423 (2006).
123. Glick SD, Maisonneuve IM. Development of novel medications for drug addiction. The legacy of an African shrub. Ann. NY Acad. Sci. 909, 88-103 (2000).
124. Ise Y, Narita M, Nagase H, Suzuki T. Modulation of opioidergic system on mecamylamine-precipitated nicotine-withdrawal aversion in rats. Psychopharmacology 151, 49-54 (2000).
125. Kiptoo PK, Paudel KS, Hammell DC, Hamad MO, Crooks PA, Stinchcomb AL. In vivo evaluation of a transdermal codrug of 6-beta-naltrexol linked to hydroxybupropion in hairless guinea pigs. Eur. J. Pharm. Sci. 33, 371-379 (2008).
126. Kwon MS, Seo YJ, Choi SM et al. The effect of formalin pretreatment on nicotine-induced antinociceptive effect: the role of mu-opioid receptor in the hippocampus. Neuroscience 154, 415-423 (2008).
127. Leedham JA, Kong JQ, Taylor DA, Johnson SM, Fleming WW. Membrane potential in myenteric neurons associated with tolerance and dependence to morphine. J. Pharmacol. Exp. Ther. 263, 15-19 (1992).
128. Maisonneuve IM, Glick SD. (+/-)Cyclazocine blocks the dopamine response to nicotine. Neuroreport 10, 693-696 (1999).
129. Marco EM, Granstrem O, Moreno E et al. Subchronic nicotine exposure in adolescence induces long-term effects on hippocampal and striatal cannabinoid-CB1 and mu-opioid receptors in rats. Eur. J. Pharmacol. 557, 37-43 (2007).
130. Miller DK, Lever JR, Rodvelt KR, Baskett JA, Will MJ, Kracke GR. Lobeline, a potential pharmacotherapy for drug addiction, binds to mu opioid receptors and diminishes the effects of opioid receptor agonists. Drug Alcohol Depend. 89, 282-291 (2007).
131. Simons CT, Cuellar JM, Moore JA et al. Nicotinic receptor involvement in antinociception induced by exposure to cigarette smoke. Neurosci. Lett. 389, 71-76 (2005).
132. Suh HW, Song DK, Choi SR, Chung KM, Kim YH. Nicotine enhances morphine- and beta-endorphin-induced antinociception at the supraspinal level in the mouse. Neuropeptides 30, 479-484 (1996).
133. Taylor DA, Leedham JA, Bennett LE, Fleming WW. Effects of GABA in the morphine-tolerant longitudinal muscle, myenteric plexus preparation of the guinea pig. J. Pharmacol. Exp. Ther. 259, 1094-1101 (1991).
134. Venihaki M, Gravanis A, Margioris AN. Opioids inhibit dopamine secretion from PC12 rat pheochromocytoma cells in a naloxone-reversible manner. Life Sci. 58, 75-82 (1996).
135. Vihavainen T, Piltonen M, Tuominen RK, Korpi ER, Ahtee L. Morphine-nicotine interaction in conditioned place preference in mice after chronic nicotine exposure. Eur. J. Pharmacol. 587, 169-174 (2008).
136. Walters CL, Cleck JN, Kuo YC, Blendy JA. Mu-opioid receptor and CREB activation are required for nicotine reward. Neuron 46, 933-943 (2005).
137. Wewers ME, Dhatt RK, Snively TA, Tejwani GA. The effect of chronic administration of nicotine on antinociception, opioid receptor binding and met-enkelphalin levels in rats. Brain Res. 822, 107-113 (1999).
138. Yoo JH, Cho JH, Lee SY, Loh HH, Ho IK, Jang CG. Reduced nNOS expression induced by repeated nicotine treatment in mu-opioid receptor knockout mice. Neurosci. Lett. 380, 70-74 (2005).
139. Yoshida M, Yokoo H, Tanaka T et al. Facilitatory modulation of mesolimbic dopamine neuronal activity by a mu-opioid agonist and nicotine as examined with in vivo microdialysis. Brain Res. 624, 277-280 (1993).
140. Robledo P, Mendizabal V, Ortuno J, de la Torre R, Kieffer BL, Maldonado R. The rewarding properties of MDMA are preserved in mice lacking mu-opioid receptors. Eur. J. Neurosci. 20, 853-858 (2004).
141. Berrettini WH, Lerman CE. Pharmacotherapy and pharmacogenetics of nicotine dependence. Am. J. Psychiatry 162, 1441-1451 (2005).
142. Gianoulakis C. Endogenous opioids and addiction to alcohol and other drugs of abuse. Curr. Top. Med. Chem. 9, 999-1015 (2009).
143. WHO. WHO report on the global tobacco epidemic, 2011: warning about the dangers of tobacco (2011). http://whqlibdoc.who.int/publications/2011/ 9789240687813-eng.pdf
144. USDHHS. The Health Benefits of Smoking Cessation. (Eds) US Dept of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health (1990). http://profiles.nlm.nih.gov/ps/access/ NNBBCV.pdf
145. Hindorff LA, Junkins HA, Hall PN, Mehta JP, Manolio TA. A catalog of published genome-wide association studies. www.genome.gov/gwastudies